Literature DB >> 8674037

H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein.

L A Doyle1, W Yang, A K Rishi, Y Gao, D D Ross.   

Abstract

The multidrug resistance phenotype of human breast carcinoma MCF-7/AdrVp cells is characterized by overexpression of a 95-kilodalton membrane glycoprotein (p95), accompanied by a marked reduction in intracellular anthracycline accumulation, without overexpression of P-glycoprotein or the multidrug resistance protein. We discovered that the mRNA of the H19 gene is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells or drug-sensitive MCF-7/AdrVp revertant cells. H19 is an imprinted gene with an important role in fetal differentiation, as well as a postulated function as a tumor suppressor gene. Another p95-overexpressing multidrug-resistant cell line, human lung carcinoma NCI-H1688, also displays high levels of H19 mRNA. In contrast, several multidrug-resistant cell lines that overexpress P-glycoprotein or the multidrug resistance protein do not have higher levels of H19 mRNA than their drug-sensitive counterparts. This is the first report of H19 gene overexpression accompanying any form of drug resistance. The association of H19 and p95 gene expression in drug resistance warrants further study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674037

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Insights from Global Analyses of Long Noncoding RNAs in Breast Cancer.

Authors:  Andrew J Warburton; David N Boone
Journal:  Curr Pathobiol Rep       Date:  2017-01-23

2.  Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue.

Authors:  Bruno Stuhlmüller; Elke Kunisch; Juliane Franz; Lorena Martinez-Gamboa; Maria M Hernandez; Axel Pruss; Norbert Ulbrich; Volker A Erdmann; Gerd R Burmester; Raimund W Kinne
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

3.  Identifying specific Notch1 target proteins in lung carcinoma cells.

Authors:  Wael Abdo Hassan; Takaaki Ito
Journal:  Histol Histopathol       Date:  2020-10-23       Impact factor: 2.303

Review 4.  The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision.

Authors:  Imad J Matouk; David Halle; Eli Raveh; Michal Gilon; Vladimir Sorin; Avraham Hochberg
Journal:  Oncotarget       Date:  2016-01-26

5.  Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.

Authors:  Qi Wang; Ningning Cheng; Xuefei Li; Hui Pan; Chunyu Li; Shengxiang Ren; Chunxia Su; Weijing Cai; Chao Zhao; Limin Zhang; Caicun Zhou
Journal:  Oncotarget       Date:  2017-01-10

6.  Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer.

Authors:  Yudong Li; Baoxiao Wang; Hongna Lai; Shunying Li; Qiuting You; Yichao Fang; Qian Li; Yujie Liu
Journal:  Thorac Cancer       Date:  2017-08-23       Impact factor: 3.500

7.  The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women.

Authors:  Tamina Elias-Rizk; Joelle El Hajj; Evelyne Segal-Bendirdjian; George Hilal
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 8.  The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers.

Authors:  Xun Zhang; Mingpeng Luo; Jiahang Zhang; Bize Guo; Shreya Singh; Xixi Lin; Hanchu Xiong; Siwei Ju; Linbo Wang; Yulu Zhou; Jichun Zhou
Journal:  Front Genet       Date:  2022-09-27       Impact factor: 4.772

9.  The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.

Authors:  Zhi-Guo Zheng; Hong Xu; Sha-Sha Suo; Xiao-Li Xu; Mao-Wei Ni; Lin-Hui Gu; Wei Chen; Liang-Yan Wang; Ye Zhao; Bing Tian; Yue-Jin Hua
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

Review 10.  The functional role of long noncoding RNA in resistance to anticancer treatment.

Authors:  Yidi Qu; Hor-Yue Tan; Yau-Tuen Chan; Hongbo Jiang; Ning Wang; Di Wang
Journal:  Ther Adv Med Oncol       Date:  2020-06-01       Impact factor: 8.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.